Cargando…

The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis

Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Yong, Qin, Di, Wang, Yudi, Xue, Lian, Qin, YaXuan, Xu, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871354/
https://www.ncbi.nlm.nih.gov/pubmed/36703925
http://dx.doi.org/10.3389/fphys.2022.1081920
_version_ 1784877152312754176
author Peng, Yong
Qin, Di
Wang, Yudi
Xue, Lian
Qin, YaXuan
Xu, Xin
author_facet Peng, Yong
Qin, Di
Wang, Yudi
Xue, Lian
Qin, YaXuan
Xu, Xin
author_sort Peng, Yong
collection PubMed
description Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF). Methods: According to the participant, intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 inhibitor administration on VO(2) or VO(2)peak were researched in this study. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated (random-effects model). Heterogeneity was assessed by the I(2) test. Results: Six studies were included according to the eligibility criteria: four were RCTs, and two were non-RCTs. Compared with the control group, the merge results of RCTs showed that SGLT-2 inhibitors could significantly increase the VO(2)peak (WMD, 2.02 ml kg(−1) min(−1), 95% CI: 0.68–3.37, and p = 0.03; I(2) = 0% and p = 0.40) and VAT (WMD, 1.57 ml kg(−1) min(−1), 95% CI: 0.06–3.07, and p = 0.04; I(2) = 0% and p = 0.52) of the obese population, patients with T2DM, and chronic HF patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors improved the VO(2)peak in non-HF patients (WMD, 3.57 ml kg(−1) min(−1), 95% CI: 0.87–6.26, and p = 0.009; I(2) = 4% and p = 0.31) more than in HF patients (WMD, 1.46 ml kg(−1) min(−1), 95% CI: −0.13–3.04, and p = 0.07; I(2) = 0% and p = 0.81). Moreover, the merge of single-arm studies also indicated that empagliflozin could improve VO(2)peak (MD, 1.11 ml kg(−1) min(−1), 95% CI: 0.93–1.30, and p = 0.827, Δ p = 0.000 and I(2) = 0%) of T2DM patients with chronic HF. Conclusion: Despite the limited number of studies and samples involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors could improve some parameters of exercise capacity (VO(2)peak, VAT) in chronic HF patients with or without T2DM and obese individuals, which had a positive effect on promoting cardiopulmonary fitness to help these populations improve their prognosis. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42020202788].
format Online
Article
Text
id pubmed-9871354
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98713542023-01-25 The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis Peng, Yong Qin, Di Wang, Yudi Xue, Lian Qin, YaXuan Xu, Xin Front Physiol Physiology Objective: The study aimed to evaluate the effect of sodium–glucose transporter 2 (SGLT-2) inhibitors on various parameters of exercise capacity and provide an evidence-based basis for type 2 diabetes mellitus (T2DM) combined with heart failure (HF) patients or HF patients without T2DM who use SGLT-2 inhibitors to improve cardiorespiratory fitness (CRF). Methods: According to the participant, intervention, comparison, and outcome (PICO) elements, the effects of SGLT-2 inhibitor administration on VO(2) or VO(2)peak were researched in this study. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were calculated (random-effects model). Heterogeneity was assessed by the I(2) test. Results: Six studies were included according to the eligibility criteria: four were RCTs, and two were non-RCTs. Compared with the control group, the merge results of RCTs showed that SGLT-2 inhibitors could significantly increase the VO(2)peak (WMD, 2.02 ml kg(−1) min(−1), 95% CI: 0.68–3.37, and p = 0.03; I(2) = 0% and p = 0.40) and VAT (WMD, 1.57 ml kg(−1) min(−1), 95% CI: 0.06–3.07, and p = 0.04; I(2) = 0% and p = 0.52) of the obese population, patients with T2DM, and chronic HF patients with or without T2DM. Subgroup analysis showed that SGLT-2 inhibitors improved the VO(2)peak in non-HF patients (WMD, 3.57 ml kg(−1) min(−1), 95% CI: 0.87–6.26, and p = 0.009; I(2) = 4% and p = 0.31) more than in HF patients (WMD, 1.46 ml kg(−1) min(−1), 95% CI: −0.13–3.04, and p = 0.07; I(2) = 0% and p = 0.81). Moreover, the merge of single-arm studies also indicated that empagliflozin could improve VO(2)peak (MD, 1.11 ml kg(−1) min(−1), 95% CI: 0.93–1.30, and p = 0.827, Δ p = 0.000 and I(2) = 0%) of T2DM patients with chronic HF. Conclusion: Despite the limited number of studies and samples involved, the meta-analysis preliminarily demonstrated that SGLT-2 inhibitors could improve some parameters of exercise capacity (VO(2)peak, VAT) in chronic HF patients with or without T2DM and obese individuals, which had a positive effect on promoting cardiopulmonary fitness to help these populations improve their prognosis. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/#recordDetails], identifier [CRD42020202788]. Frontiers Media S.A. 2023-01-10 /pmc/articles/PMC9871354/ /pubmed/36703925 http://dx.doi.org/10.3389/fphys.2022.1081920 Text en Copyright © 2023 Peng, Qin, Wang, Xue, Qin and Xu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Peng, Yong
Qin, Di
Wang, Yudi
Xue, Lian
Qin, YaXuan
Xu, Xin
The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title_full The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title_fullStr The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title_full_unstemmed The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title_short The effect of SGLT-2 inhibitors on cardiorespiratory fitness capacity: A systematic review and meta-analysis
title_sort effect of sglt-2 inhibitors on cardiorespiratory fitness capacity: a systematic review and meta-analysis
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871354/
https://www.ncbi.nlm.nih.gov/pubmed/36703925
http://dx.doi.org/10.3389/fphys.2022.1081920
work_keys_str_mv AT pengyong theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT qindi theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT wangyudi theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT xuelian theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT qinyaxuan theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT xuxin theeffectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT pengyong effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT qindi effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT wangyudi effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT xuelian effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT qinyaxuan effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis
AT xuxin effectofsglt2inhibitorsoncardiorespiratoryfitnesscapacityasystematicreviewandmetaanalysis